IQV

IQVIA Holdings Inc

Add to Watchlist

Advanced Chart

179.860

+0.91(0.509%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

180.4031

Open

178.840

VWAP

179.54

Vol

877.75K

Mkt Cap

30.58B

Low

177.900

Amount

157.59M

EV/EBITDA(TTM)

12.92

Total Shares

182.20M

43.73B

EV/OCF(TTM)

16.71

P/S(TTM)

2.04

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

4.06B

+6%

2.935

+8.71%

4.24B

+7.07%

3.390

+8.65%

4.07B

+4.51%

2.983

+5.03%

Estimates Revision

The market is revising Upward the revenue expectations for IQVIA Holdings Inc. (IQV) for FY2025, with the revenue forecasts being adjusted by 0.54% over the past three months. During the same period, the stock price has changed by 20.72%.

Revenue Estimates for FY2025

Revise Upward

+0.54%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.08%

In Past 3 Month

Stock Price

Go Up

+20.72%

In Past 3 Month

15 Analyst Rating

-1.42% Downside

Wall Street analysts forecast IQV stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IQV is 177.31 USD with a low forecast of 159.00 USD and a high forecast of 211.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

4 Hold

0 Sell

Moderate Buy

-1.42% Downside

Current: 179.860

Low

159.00

Averages

177.31

High

211.00

-1.42% Downside

Current: 179.860

Low

159.00

Averages

177.31

High

211.00

Mizuho

Ann Hynes

Outperform

maintain

$190 -> $225

2025-07-25

Reason

Mizuho

Ann Hynes

Price Target

$190 -> $225

2025-07-25

maintain

Outperform

Reason

Mizuho analyst Ann Hynes raised the firm's price target on Iqvia to $225 from $190 and keeps an Outperform rating on the shares. The company's booking trends were stable in the quarter, much better than feared, the analyst tells investors in a research note. The firm says that when coupled with improved cancelation rates and an improvement in trial delays, there is increased earnings visibility for 2026.

Barclays

Equal Weight

maintain

$165 -> $185

2025-07-23

Reason

Barclays

Price Target

$165 -> $185

2025-07-23

maintain

Equal Weight

Reason

Barclays raised the firm's price target on Iqvia to $185 from $165 and keeps an Equal Weight rating on the shares following the Q2 report. Barclays says that while Iqvia's bookings beat expectations, it is not ready to call the bottom yet on biotechs.

Baird

Neutral

maintain

$159 -> $196

2025-07-23

Reason

Baird

Price Target

$159 -> $196

2025-07-23

maintain

Neutral

Reason

Baird raised the firm's price target on Iqvia to $196 from $159 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results.

Truist

Jailendra Singh

Buy

maintain

$209 -> $235

2025-07-23

Reason

Truist

Jailendra Singh

Price Target

$209 -> $235

2025-07-23

maintain

Buy

Reason

Truist analyst Jailendra Singh raised the firm's price target on Iqvia to $235 from $209 and keeps a Buy rating on the shares. Iqvia reported strong results given the backdrop, the analyst tells investors in a research note.

UBS

Dan Leonard

Buy

maintain

$185 -> $225

2025-07-23

Reason

UBS

Dan Leonard

Price Target

$185 -> $225

2025-07-23

maintain

Buy

Reason

UBS analyst Dan Leonard raised the firm's price target on Iqvia to $225 from $185 and keeps a Buy rating on the shares. In a slightly more supportive environment, some share gains offset margin pressure, the analyst tells investors in a research note.

Evercore ISI

Outperform

maintain

$180 -> $220

2025-07-23

Reason

Evercore ISI

Price Target

$180 -> $220

2025-07-23

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on Iqvia to $220 from $180 and keeps an Outperform rating on the shares. The firm says Iqvia is riding high on an improved demand trajectory in pharma and biotech services, with strong Q2 results boosting confidence for 2025 and beyond. The positive momentum is fueled by solid R&DS revenues and better-than-expected TAS performance, particularly in analytics, consulting, and tech, Evercore adds.

See All Ratings

Valuation Metrics

The current forward P/E ratio for IQVIA Holdings Inc (IQV.N) is 14.49, compared to its 5-year average forward P/E of 20.71. For a more detailed relative valuation and DCF analysis to assess IQVIA Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

20.71

Current PE

14.49

Overvalued PE

24.23

Undervalued PE

17.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

14.93

Current EV/EBITDA

11.27

Overvalued EV/EBITDA

17.23

Undervalued EV/EBITDA

12.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.66

Current PS

1.82

Overvalued PS

3.10

Undervalued PS

2.22